MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

TG Therapeutics Inc

Отворен

СекторЗдравеопазване

40.73 1.39

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

39.33

Максимум

41.01

Ключови измерители

By Trading Economics

Приходи

19M

23M

Продажби

24M

108M

P/E

Средно за сектора

246.467

57.333

EPS

0.15

Марж на печалбата

21.566

Служители

338

EBITDA

17M

33M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+6.7% upside

Дивиденти

By Dow Jones

Следващи печалби

30.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

912M

5.8B

Предишно отваряне

39.34

Предишно затваряне

40.73

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

TG Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.08.2024 г., 20:01 ч. UTC

Печалби

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Сравнение с други в отрасъла

Ценова промяна

TG Therapeutics Inc Прогноза

Ценова цел

By TipRanks

6.7% нагоре

12-месечна прогноза

Среден 43 USD  6.7%

Висок 55 USD

Нисък 11 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за TG Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

5

Купи

0

Задържане

1

Продай

Техническа оценка

By Trading Central

38.41 / 40.35Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.